Fig. 1 · Structure

Documents & Downloads

MK-0812

Cat. No. A11127 CAS 624733-88-6

CCR2 antagonist

MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes and low nM in the chemotaxis assay. It has good PK profiles in preclinical species and demonstrated efficacy in animal models.

In Stock

Publications for MK-0812

1 publication citing this product

  1. Murakami K, .et al. , Vet Immunol Immunopathol, 2016, Dec;182:52-58 PMID: 27863550

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In experiments using MK-0812 as a CCR2 antagonist, 1 μM MK-0812 did not significantly change constitutive CCR2 internalization in primary human monocytes. Receptor turnover therefore remained detectable during antagonist treatment. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CCR2  

MK-0812 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of MK-0812 from 2 published references.

MK-0812 In Vitro Studies

In MDA-MB-231 breast-cancer cells, 600 nM MK-0812 reduced the ALDEFLUOR-bright population stimulated by post-neoadjuvant-treatment patient sera. This is a cultured-cell marker response, with paired serum and vehicle controls. [2]

MK-0812 leaves constitutive CCR2 internalization intact

Cell-based study · Fresh primary human peripheral-blood monocytes; pre-label and post-label flow-cytometry protocols [1]

MK-0812 did not significantly alter surface CCR2 turnover in the 30-minute comparison. Pre-labeled surface receptor signal declined at 37°C while post-incubation labeling detected maintained surface receptor levels. The time course likewise showed ongoing internalization in the presence of MK-0812.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Surface CCR2 signal and constitutive internalizationqualitative response No significant difference among the tested treatment conditions in Figure 6A; internalization persisted with MK-0812 in Figure 6B.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
Figure 6A: 30 min at 37°C, with a 4°C reference; Figure 6B: 1 h antagonist pre-treatment followed by the displayed internalization time course.
Method
CCR2 antibody pre-label/post-label assay
Vehicle
Methods specify DMSO vehicle; Figure 6 explicitly includes PBS control.
Co-treatment
MK-0812 was tested alone; CCX598 and other control conditions were separate comparators.
Reported limits
Final DMSO fraction and biological identity of the three replicates in Figure 6A are not specified. Figure 6B replicate number is not specified.
Methods and source locations

Compound reported in the paper: MK-0812; Compound label in the paper: MK-0812

Evidence concerns the named literature compound. It does not validate an Adooq lot, establish analytical stereochemical equivalence, or demonstrate a particular salt form. Reported doses are retained without salt conversion.

Figure 6A-B and caption; Results paragraph beginning "A clue towards the mechanism"; Methods: Receptor Internalization Assay; Reagents

Surface CCR2 signal and constitutive internalization: Anti-CCR2 labeling before versus after incubation; flow cytometry. Figure 6A reports three replicates as mean ± SEM; donor independence of those replicates is not specified. — Figure 6A-B and caption; Results paragraph beginning "A clue towards the mechanism"; Methods: Receptor Internalization Assay; Reagents

MK-0812 suppresses serum-induced ALDEFLUOR enrichment

Cell-based study · MDA-MB-231 human breast-cancer cells exposed to paired pre-/post-neoadjuvant-treatment patient sera; six illustrated serum pairs in Figure 1D [2]

MK-0812 reduced the ALDEFLUOR-bright population induced by post-treatment sera in the six illustrated cases. This cultured-cell assay used human serum as a stimulus; it is not a patient treatment experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ALDEFLUOR-bright fraction of MDA-MB-231 cellsqualitative response Reduced in the MK-0812 condition compared with the corresponding vehicle condition for the illustrated post-treatment sera.[2]

Literature-Reported Treatment Conditions

Treatment concentration
600 nM
Exposure duration
48 h serum exposure in the shared Figure 1A assay description.
Method
Cell culture with 10% patient serum replacing FBS; ALDEFLUOR flow cytometry.
Vehicle
Vehicle comparator; vehicle composition is not stated for Figure 1D.
Co-treatment
Patient serum stimulus; MK-0812 versus vehicle within paired serum conditions.
Reported limits
Figure 1D does not specify assay replicate number or vehicle composition. The 20 serum pairs in Figure 1A-B must not be assigned as n for Figure 1D.
Methods and source locations

Compound reported in the paper: MK-0812; Compound label in the paper: CCR2 inhibitor / CCR2i (MK-0812)

Evidence concerns the named literature compound. It does not validate an Adooq lot, establish analytical stereochemical equivalence, or demonstrate a particular salt form. Reported doses are retained without salt conversion.

Figure 1D, shared Figure 1A assay description and caption; first Results subsection; Methods: Cells and constructs, Flow cytometry and cell sorting, Statistics

ALDEFLUOR-bright fraction of MDA-MB-231 cells: ALDEFLUOR kit and flow cytometry. Figure 1D viewed; six cases are shown. Shared Statistics states mean ± SD; technical/biological replicate number for this panel is not specified. — Figure 1D, shared Figure 1A assay description and caption; first Results subsection; Methods: Cells and constructs, Flow cytometry and cell sorting, Statistics

MK-0812 In Vivo Studies

Single oral doses of MK-0812 increased plasma CCL2 in wild-type C57BL/6 mice at four hours. This pharmacodynamic response should be distinguished from disease improvement. [1]

In NSG mice bearing MDA-MB-231 xenografts, oral MK-0812 given with a three-week docetaxel course reduced subsequent tumor regrowth and the tumor ALDEFLUOR-bright fraction compared with docetaxel plus vehicle. The result is specific to the combination design. [2]

Oral MK-0812 increases plasma CCL2 in mice

Animal study · Female C57BL/6 mice, 4–6 weeks old; n = 5 per group in Methods [1]

At four hours after oral MK-0812, plasma CCL2 increased in the dose-ranging experiment. Drug exposure was assessed in the same plasma samples. This is a pharmacodynamic result, not a disease-efficacy test.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma CCL2 four hours after dosingreported approximate plateau and response direction Plasma CCL2 increased with MK-0812; the Results describe a plateau near 300 pg/ml.[1]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Single dose
Treatment course
4 h to the adopted plasma endpoint
Vehicle
1% HPMC
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MK-0812 dose range
0.1, 10 or 30 mg/kg (separate dose groups)
Wild-type mice receiving vehicle; untreated wild-type mice also shown in Figure 1A.Plasma CCL2 increased; LC-MS/MS confirmed plasma MK-0812 exposure in Figure 1B.[1]
MK-0812 dose range
Model: Female wild-type C57BL/6 mice
Reported limits: No disease-severity endpoint is part of this experiment; Figure 1A error-bar definition is not given.
Methods and source locations

Compound reported in the paper: MK-0812; Compound label in the paper: MK-0812

Evidence concerns the named literature compound. It does not validate an Adooq lot, establish analytical stereochemical equivalence, or demonstrate a particular salt form. Reported doses are retained without salt conversion.

Figure 1A-B and caption; first Results paragraph; Methods: In Vivo Studies; Reagents

Plasma CCL2 four hours after dosing: CCL2 ELISA; Figure 1A viewed. The approximate plateau is explicitly reported in Results, not inferred as an exact value from the graph. — Figure 1A-B and caption; first Results paragraph; Methods: In Vivo Studies; Reagents

MK-0812 dose range · Figure 1A-B and caption; first Results paragraph; Methods: In Vivo Studies; Reagents

MK-0812 co-treatment limits post-docetaxel xenograft regrowth

Animal study · Female NSG mice bearing orthotopic MDA-MB-231-shCTRL xenografts; n = 8 for tumor-volume data (Figure 4B) [2]

Adding oral MK-0812 during the docetaxel course reduced subsequent tumor regrowth and the ALDEFLUOR-bright fraction relative to docetaxel plus vehicle. The design does not establish MK-0812 monotherapy efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Post-chemotherapy tumor regrowthqualitative response Reduced with MK-0812 plus docetaxel versus docetaxel plus vehicle.[2]
ALDEFLUOR-bright fraction in dissociated tumorsqualitative response Lower with MK-0812 plus docetaxel than with docetaxel plus vehicle.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Docetaxel plus MK-0812
MK-0812 30 mg/kg per administration; docetaxel dose for this design not restated
Docetaxel plus vehicle in the same shCTRL tumor modelReduced post-therapy tumor regrowth and lower tumor ALDEFLUOR-bright fraction.[2]
Docetaxel plus vehicle
Docetaxel dose for this design not restated; MK-0812 absent
Reference comparator for the MK-0812 co-treatment groupGreater tumor regrowth and higher ALDEFLUOR-bright fraction than the MK-0812 co-treatment group.[2]
Docetaxel plus MK-0812
Model: NSG mice with MDA-MB-231-shCTRL tumors
Route: MK-0812 oral; docetaxel route not separately specified for Figure 4A-C
Frequency: MK-0812 twice daily; docetaxel weekly for 3 weeks
Treatment course: MK-0812 30 days from chemotherapy initiation
Vehicle: Not specified
Reported limits: Vehicle composition and the docetaxel dose specifically assigned to Figure 4A-C are not restated. Figure 4B reports n = 8; Figure 4C does not separately specify n. The schematic and prose differ on the approximate starting tumor size, which is not used in this record.
Docetaxel plus vehicle
Model: NSG mice with MDA-MB-231-shCTRL tumors
Route: Vehicle and docetaxel routes not separately specified for Figure 4A-C
Frequency: Docetaxel weekly for 3 weeks; vehicle schedule not separately stated
Treatment course: Docetaxel on days 24, 31 and 38; comparator followed for regrowth
Vehicle: Composition not specified
Reported limits: Vehicle composition and the docetaxel dose specifically assigned to Figure 4A-C are not restated. Figure 4B reports n = 8; Figure 4C does not separately specify n. The schematic and prose differ on the approximate starting tumor size, which is not used in this record.
Methods and source locations

Compound reported in the paper: MK-0812; Compound label in the paper: CCR2 inhibitor / CCR2i (MK-0812)

Evidence concerns the named literature compound. It does not validate an Adooq lot, establish analytical stereochemical equivalence, or demonstrate a particular salt form. Reported doses are retained without salt conversion.

Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics

Post-chemotherapy tumor regrowth: Caliper tumor-volume measurements; Figure 4B. n = 8; shared Statistics states mean ± SD. — Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics

ALDEFLUOR-bright fraction in dissociated tumors: ALDEFLUOR flow cytometry; Figure 4C. Panel-specific replicate number is not separately specified. — Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics

Docetaxel plus MK-0812 · Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics

Docetaxel plus vehicle · Figure 4A-C and caption; Results: Chemotherapy promotes CSC properties in vivo through MCP-CCR2 signaling; Methods: Animals, Cells and constructs, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 624733-88-6
Applications CCR2 antagonist
Formula C24H34F3N3O3
Molecular Weight 469.5
SMILES
CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=NC=C(C=C4C3)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MK-0812 Research References

  1. [1] Zhao BN, Campbell JJ, Salanga CL, et al. CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood. Journal of immunology (Baltimore, Md. : 1950) (2019). PMID: 31676674 DOI: 10.4049/jimmunol.1900961 Source material
  2. [2] Liu L, Yang L, Yan W, et al. Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29500278 DOI: 10.1158/1078-0432.ccr-17-2545 Source material

Publications

1 publication citing this product

  1. Murakami K, .et al. , Vet Immunol Immunopathol, 2016, Dec;182:52-58 PMID: 27863550

Added to your cart

View Cart Checkout
Loading...